Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603498 | 1.00 | SMN1; SMN2 (0.33) | SMN1; SMN2HTTKMT2AS1PR1S1PR3 | |
| SCHEMBL22771018 | 0.84 | SMN1; SMN2 (0.35) | SMN1; SMN2HTTKMT2AS1PR1S1PR3 | |
| SCHEMBL15699752 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2HTTKMT2AS1PR1S1PR3 | |
| SCHEMBL17427757 | 0.78 | NOS3 (0.39) | SMN1; SMN2HTTKMT2AHSD17B10 | |
| SCHEMBL31145165 | 0.76 | KDM4E (0.46) | SMN1; SMN2HTTKMT2AHSD17B10 | |
| SCHEMBL15004184 | 0.76 | KDM4E (0.46) | SMN1; SMN2HTTKMT2AHSD17B10 | |
| SCHEMBL2066694 | 0.76 | HTT (0.39) | SMN1; SMN2HTTKMT2AS1PR1S1PR3 | |
| SCHEMBL28166044 | 0.76 | SMN1; SMN2 (0.35) | SMN1; SMN2HTTKMT2AS1PR1S1PR3 | |
| SCHEMBL30403001 | 0.74 | SMN1; SMN2 (0.34) | SMN1; SMN2HTTKMT2AHSD17B10 | |
| Methyl Alcohol SCHEMBL10757708 | 0.74 | NOS3 (0.37) | SMN1; SMN2HTTKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447503-B2 | Pyridine carbamates and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-20 | — | — | US | disclosed |
| EP-3983074-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020249799-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392154-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447503-B2 | Pyridine carbamates and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN1 | SMN1; SMN2 1492/4885HTT 824/4885KMT2A 1397/4885 |
| US-20200392154-A1 | PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN1 | SMN1; SMN2 1492/4885HTT 824/4885KMT2A 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.